Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Advanced or metastatic solid tumors · Waldenström's Macroglobulinemia

BeiGene

BeiGene patent portfolio — 25 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US HQ
2010 Founded
2,047 Employees
NMPA registrant Type
Company details
Status
Public
HQ
55 Cambridge Parkway, Suite 700W, Cambridge, MA 02142, US
Founded
2010
Employees
2,047
Programs
14
Drugs
19
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Patents

BeiGene patents

25 pharmaceutical patents indexed for BeiGene. 0 expire within 24 months.

BeiGene has 25 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

25 patents

Patent portfolio

  1. AU 2025242171

    A Medicament and Method of Treatment of Central Nervous System and/or Neuropsychiatric Disorders

    Expires Wed Dec 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. WO 2025252204

    DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF

    Expires Wed Dec 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2025232885

    PROCÉDÉ DE PRÉPARATION D'UN AGENT DE DÉGRADATION DE LA TYROSINE KINASE DE BRUTON

    Expires Wed Nov 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2025218772

    FORMES SOLIDES COMPRENANT UN AGENT DE DÉGRADATION DE TYROSINE KINASE DE BRUTON ET LEURS UTILISATIONS

    Expires Wed Oct 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2025214466

    CONJUGUÉS DE PYRROLOBENZODIAZÉPINE CIBLÉS

    Expires Wed Oct 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2025304535

    KAT6 Inhibitors

    Expires Wed Sep 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2025201453

    COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE RAS

    Expires Wed Sep 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 2025290040

    GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE

    Expires Wed Sep 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2025168072

    COMPOSÉS HÉTÉROCYCLIQUES, COMPOSITIONS ASSOCIÉES ET MÉTHODES DE TRAITEMENT ASSOCIÉS

    Expires Wed Aug 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. WO 2025168081

    TRAITEMENT D'UN TROUBLE PROLIFÉRATIF DES LYMPHOCYTES B AVEC UN COMPOSÉ ACTIVATEUR DE DÉGRADATION CHIMÉRIQUE

    Expires Wed Aug 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 2025222125

    Anti-FGFR2b Antibodies, Conjugates and Methods of Use

    Expires Wed Jul 05 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. WO 2025126115

    DÉGRADATION DE L'IRAK4 PAR CONJUGAISON D'INHIBITEURS D'IRAK4 AVEC DES LIGANDS DE LIGASE E3 ET PROCÉDÉS D'UTILISATION

    Expires Wed Jun 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. TW 202523278

    Antibody drug conjugate platforms

    Expires Sun Jun 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. WO 2025108443

    COMPOSÉS HÉTÉROCYCLIQUES ET COMPOSITIONS ASSOCIÉES, ET MÉTHODES DE TRAITEMENT CORRESPONDANTES

    Expires Thu May 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. CN 119857078

    PARP inhibitor child preparation and preparation process thereof

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. WO 2025078995

    COMPOSÉS DE 6-(PYRIMIDIN-4-YL)QUINOLÉINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASE DÉPENDANTE DE LA CYCLINE

    Expires Wed Apr 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. WO 2025077836

    LIPIDES IONISABLES ET NANOPARTICULES LIPIDIQUES POUR ADMINISTRATION D'ARN

    Expires Wed Apr 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. TW 202515875

    Solid forms comprising a B-RAF kinase dimer inhibitor, methods of preparation, and uses therefor

    Expires Tue Apr 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. TW 202515903

    Anti-PD-1-based treatment before and after surgery

    Expires Tue Apr 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. WO 2025068985

    DÉRIVÉS DE 1-(1-OXO-1,2-DIHYDROPHTALAZIN-6-YL)CYCLOALKYL-1-CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS COOPÉRATIFS DE MTA DE PRMT5

    Expires Wed Mar 29 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. TW 202513047

    KAT6 inhibitors

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. WO 2025062334

    DÉRIVÉS DE 4-((5-(3-(4-(PYRIDIN-2-YL)CYCLOPENTYL)-1 H-PYRAZOL-3-YL)AMINO)-BENZÈNESULFONAMIDE ET COMPOSÉS SIMILAIRES UTILISÉS COMME INHIBITEURS DE CDK POUR LE TRAITEMENT DU CANCER

    Expires Wed Mar 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. WO 2025052303

    ARN CIRCULAIRE ET PROCÉDÉS DE PRÉPARATION ASSOCIÉS

    Expires Wed Mar 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. WO 2025041076

    COMPOSÉS BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE CDK

    Expires Wed Feb 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. WO 2025040080

    TRAITEMENT DU CANCER DE L'OESOPHAGE PAR ANTI-LAG3, ANTI-PD-1 ET CHIMIOTHÉRAPIE

    Expires Wed Feb 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does BeiGene have?

25 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do BeiGene patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.